2 options
Comparative clinical and economic effectiveness of anti-vascular endothelial growth factor agents / principal investigator: Allison Low ; contributing investigators: Devan Kansagara, Michele Freeman, Rochelle Fu, Kavita Bhavsar, Ambar Faridi, Karli Kondo, Robin Paynter.
Connect to full text Available online
View online- Format:
- Book
- Government document
- Author/Creator:
- Low, Allison, author.
- Series:
- Evidence-based synthesis program (Series)
- Evidence-based synthesis program
- Language:
- English
- Subjects (All):
- Vision disorders--United States.
- Vision disorders.
- Vascular endothelial growth factors--Antagonists.
- Vascular endothelial growth factors.
- Veterans--Medical care--United States.
- Veterans.
- Outcome assessment (Medical care)--United States.
- Outcome assessment (Medical care).
- Cost effectiveness.
- Retinal Diseases--drug therapy.
- Angiogenesis Inhibitors--therapeutic use.
- Vascular Endothelial Growth Factors--drug effects.
- Veterans Health.
- Comparative Effectiveness Research.
- Cost-Benefit Analysis.
- United States.
- cost benefit analysis.
- Veterans--Medical care.
- Medical Subjects:
- Retinal Diseases--drug therapy.
- Angiogenesis Inhibitors--therapeutic use.
- Vascular Endothelial Growth Factors--drug effects.
- Veterans Health.
- Comparative Effectiveness Research.
- Cost-Benefit Analysis.
- United States.
- Physical Description:
- 1 online resource (iv, 123 pages) : illustrations.
- Other Title:
- Comparative clinical and economic effectiveness of anti-VEGF agents
- Place of Publication:
- Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, January 2017.
- Summary:
- Visual impairment is a common problem among Veterans and results in significant reduction in quality of life. Diseases commonly responsible for substantial losses in visual acuity include neovascular ("wet") age-related macular degeneration (AMD), diabetic macular edema (DME), and central or branch retinal vein occlusion (CRVO or BRVO). While the etiologies of these diseases are complex, all are driven at least in part by vascular endothelial growth factors (VEGFs). This has led to the development of several drugs called anti-VEGF agents designed to block these factors and thus limit their damage to the eye. The most commonly used anti-VEGF agents--aflibercept, bevacizumab, and ranibizumab--have been shown to slow and even reverse the vision loss typically seen in patients with AMD, DME, BRVO, and CRVO. The comparative effectiveness, harms, and costs of these drugs are unclear.
- Notes:
- "January 2017."
- Includes bibliographical references (pages 76-81).
- Description based on online resource; title from PDF cover (VA, viewed December 23, 2020).
- OCLC:
- 1029858169
- Access Restriction:
- Access restricted to subscribing institutions.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.